A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.

Maaike C Swets, Rob J Moss,Flip Kor, Doranne Hilarius,Dirk Jan A R Moes, Willemijn Em Berkhout,Leon M van den Toorn,Niels C Gritters van den Oever, Renee de Valk,Frits R Rosendaal,Nicole Hunfeld,Geert H Groeneveld,Mark G J de Boer

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases（2023）

引用 0|浏览4

暂无评分

摘要

We found differences in the probability of 60-day survival and the incidence of the combined outcome of mortality or ICU admission, mostly favoring 8 mg/kg tocilizumab. Because of potential time-associated residual confounding, further clinical studies are warranted.

查看译文

关键词

COVID-19,IL-6 inhibitor,SARS-CoV-2,Sarilumab,Tocilizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要